Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGSC 20% in Japanese patients with primary immunodeficiency diseases
2022-001873-29Phase 3
- Sponsor
- Baxalta
- Start
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of IgPro20 in Immunogenetic disorder, sponsored by Baxalta. Primary endpoint: Total serum trough IgG levels during weekly IGSC 20% and biweekly IGSC 20%.
02
Drugs
IgPro20
03
Conditions
Immunogenetic disorder
Beyond the preview
Go deeper on 2022-001873-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001873-29.